News

Hengrui Medicine Helped Sino-Italian Experts Build Exchange Platform for COVID-19 Treatment

From: Lianyungang Updated: 2020-03-25 09:24

On the afternoon of March 21st, the Sino-Italian epidemic prevention clinical diagnosis and treatment experience sharing meeting with a notion of a "community of common destiny" was held in Beijing. At the meeting, clinical experts of Wuhan First Hospital shared the clinical experience of epidemic prevention and treatment with experts from Italian National Geriatric Medical and Research Institute through remote video link. And they extensively exchanged the treatment plan for COVID-19 in the elderly. Fabrizala Danzio, vice president of the National Institute of Geriatric Medicine and Science of Italy, said that they were very grateful to the Chinese doctors who attended the meeting. Chinese doctors elaborated on infection rules and diagnostic criteria of COVID-19 and shared the treatment plan for elderly patients. The meeting was facilitated by Hengrui Medicine, a pharmaceutical company in Lianyungang.

Over the years, Hengrui Medicine has accelerated the implementation of the international development strategy and actively "gone out" to establish a deep-seated and normalized cooperative relationship with top international medical institutions. These medical institutions include Mayo Clinic, Harvard Medical School and its affiliated hospital, MD Anderson Cancer Center, Cambridge University and its affiliated hospital, Ecole des Hautes Etudes en Santé Publique, Karolinska Medical School, AKH in Austria, Affiliated Hospital of Tokyo University and  etc. Hengrui Medicine also cooperates with the talent exchange service center of the National Health Commission to establish a platform and channel for international cooperation and talent training of domestic medical institutions. While promoting innovation and R & D, Hengrui Medicine also helps to train domestic medical talents and serve the development of health undertakings.